



Sino-American
Pharmaceutical
Professionals
Association

Title Sponsor

Deloitte.

2020 SAPA Healthcare Investment Forum & Roadshow



Part I: Virtual Digital Session

Saturday

June 20, 2020

Table of Contents

- 3 SAPA Introduction
- 4 Title Sponsor: Deloitte
- 5 2020 SAPA Healthcare Investment Forum & Roadshow: Overview
- 6 2020 SAPA Investment Forum and Roadshow Organizing Committee
- 7 – 9 Event Agenda
- 10 – 11 Project Lists
- 12 – 18 Biographies of the Presenters, Panelists, Investors and Roadshow Judges
- 19 – 20 Investors Participating the Forum
 - 21 Pharma and Others
 - 22 Event Sponsors
 - 23 2019-2020 SAPA Corporate Sponsors
- 24 – 31 Event Sponsor Information:
 - 24. *Bridge Point Capital*
 - 25. *Fox Rothschild*
 - 26. *Hengrui Medicine*
 - 27. *KLUS Pharma*
 - 28. *Macias Gini & O’Connell LLP (MGO)*
 - 29. *Ningbo’s Hangzhou Bay BioVillage*
 - 30. *Shanghai Medicilon*
 - 31. *WWC Professional Corporation Limited CPA*
- 32 – 34 Save the date: upcoming major SAPA Events:
 - July 18: Career Development workshop*
 - August 15: Scientific Symposium*
 - Oct 2 – 3: Annual Conference*

1:1 video meetings will be arranged in the week of June 20 using a 1:1 system.
Please Note: This Virtual Digital Session will be recorded and accessible for the registered participants until the end of June 2020.

SAPA Introduction

The Sino-American Pharmaceutical Professionals Association (SAPA) was established in 1993 and is headquartered in the center of the pharmaceutical corridor in New Jersey, USA. Since its inception, SAPA rapidly became one of the most active Chinese professional associations in the US with eight chapters and more than 6,000 members.

SAPA's members are primarily from large and mid-sized pharmaceutical and biotech companies in the US, with areas of expertise covering almost every aspect of pharmaceutical research and development as well as production.

The organization's large membership base and their superb scientific and technical abilities has allowed SAPA to be a key source for knowledge exchange on the latest developments in the pharmaceutical, biotechnology, and generic drug industries.

As a non-profit organization registered in the US, SAPA receives generous sponsorship and support from numerous multinational companies in the US and overseas. SAPA will continue to provide a broad platform for scientific and technical discussion, talent exchange, and training for the colleagues in the pharmaceutical industry from the US and China.

SAPA Sites and Chapters

- *SAPA-HQ (Headquarter): New Jersey, USA*
- *SAPA-NE (New England Chapter): Boston and New England region, USA*
- *SAPA-GP (Greater Philadelphia Chapter): Philadelphia and other Pennsylvania areas, USA*
- *SAPA-MW (Mid-West Chapter): Illinois and Indiana, USA*
- *SAPA-WEST (West Chapter): California, USA*
- *SAPA-CT (Connecticut Chapter): Connecticut, USA*
- *SAPA-DC (DC Chapter): District of Columbia and Maryland, USA*
- *SAPA-China: Zhengzhou and Beijing, China*

Professional Expertise of SAPA Members

- *Drug discovery, research and development*
- *Preclinical and clinical research and development*
- *Application and registration of new drug and biologics to the US FDA*
- *Production and manufacture of pharmaceuticals and biological products*
- *Commercial and marketing of pharmaceutical and biological products*
- *Generic product development and technology*

Deloitte.



The sky is the limit So, let's get started

Deloitte's Life Sciences and Health Care (LSHC) professionals understand the complexity of today's global industry challenges, and provide clients with integrated, comprehensive services anywhere that they do business. Navigating China's fast-growing LSHC market as well as US market entry considerations can be challenging, which is why our Chinese Services Group, a network of bilingual professionals working alongside our LSHC industry experts, can make all the difference.

Learn more at www.deloitte.com/healthcare

Copyright © 2020 Deloitte Development LLC. All rights reserved.

2020 SAPA Healthcare Investment Forum & Roadshow

Aiming to meet the needs of healthcare advancement and to bridge breakthrough science and capital investment, SAPA is hosting its 3rd annual Healthcare Investment Forum and Roadshow to focus on the latest trends and development in the area of healthcare investment. COVID-19 has brought significant challenge and disruption to our world and event planning, but the SAPA planning team has worked with the key stakeholders and is thinking outside the box to continue our efforts and divide this premium flagship event into two segments to serve the community: we will host the Part I as a virtual digital session on June 20th, 2020, and plan a Part II in conjunction with the SAPA Annual Conference on the weekend of Oct 3rd this year.

- *To promote business cooperation in the healthcare and pharmaceutical industry*
- *Learn the latest trends and outlook for life-science investment from renowned investors*
- *For entrepreneurs, learn how to attract angel investors*
- *For participants, you can observe roadshow programs where the brightest ideas meet the most ambitious capital investors*
- *Schedule 1:1 session meetings and have in-depth discussions between entrepreneurs and investors*
- *Exchange ideas and discuss business opportunities through networking sessions*

We look forward to your joining us to make it another impactful event.

2020 SAPA Investment Forum and Roadshow Organizing Committee

Event Chair:

Xiaodong Chen

Co-Chairs:

Stephen Xue	SAPA-HQ
Bin Shi	SAPA-China
Yan Yan	SAPA-CT
Lingquan Deng	SAPA-DC
Jerry Xin	SAPA-GP
Haipeng Cheng	SAPA-MW
Qiyong Hu	SAPA-NE

Committee Members:

Bob Ai	Eric Rong
Victoria Bahena	Xiaole Shen
Cynthia Cai	John Sun
JiangChao Chen	Mark Tang
Serena Chen	Xin Teng
Gang Cheng	Hui Wang
Tuochuan Dong	Jin Wang
Jiahong Fan	Xiaowen Wang
Hangfei Fu	Jack Wu
Chenchao Gao	Aiguo Xu
Pengbo Guo	Jianing Xu
Andy Han	Shuangyi Xu
May Yongmei Huang	Xiaojiao Xue
Ying Kai	Guangyao Yang
Jia Li	Xiaowei Zang
Xue Liang	Aming Zhang
Jerry Liu	Yulan Zhang
Ling Liu	Tianhao Zhao
Jiajun Mei	Yiming Zhao
Li Ren	

2020 SAPA Healthcare Investment Forum & Roadshow

Saturday, June 20, 2020

Title sponsor:

Deloitte.

9:00 am – 12:00 pm	Track #1 Entrepreneurship and Innovation Roadshow: Oral presentations
9:00 am – 9:10 am	<p>Opening Remarks Xiaodong Chen, PhD, 2020 SAPA Healthcare Investment and Roadshow Chair; SAPA Executive Vice President; Drug Product Development Team Lead, BMS</p> <p>SAPA Introduction Wansheng Jerry Liu, PhD, JD, SAPA President; Partner and the Chair of China Practice Group of Fox Rothschild LLP</p>
9:10 am – 9:15 am	<p>Introduce the SAPA Investment Forum and Roadshow with Agenda, Introduce Roadshow Judges Xiaodong Chen, PhD, 2020 SAPA Healthcare Investment and Roadshow Chair; SAPA Executive Vice President; Drug Product Development Team Lead, BMS</p>
9:15 am – 9:30 am	Roadshow Project 1: KLUS Pharma
9:30 am – 9:45 am	Roadshow Project 2: HbO2 Therapeutics LLC
9:45 am – 10:00 am	Roadshow Project 3: Clerio Vision
10:00 am – 10:15 am	Roadshow Project 4: Phase Scientific International Limited
10:15 am – 10:30 am	Roadshow Project 5: Innovative Cellular Therapeutics, Inc.
10:30 am – 10:40 am	<i>Coffee Break</i>
10:40 am – 10:55 am	Roadshow Project 6: Biosion, Inc.
10:55 am – 11:10 am	Roadshow Project 7: Misum Biotech
11:10 am – 11:25 am	Roadshow Project 8: Teon Therapeutics, Inc.
11:25 am – 11:40 am	Roadshow Project 9: LinkedUp Bioscience
11:40 am – 11:55 am	Roadshow Project 10: Quantapore
11:55 am – 12:00 pm	Sponsor remarks and roadshow award results
12:00 pm – 1:00 pm	<i>Lunch Break</i>

1:00 pm – 4:00 pm

Track #2 Plenary Session and Fireside Chats

1:00 pm – 1:20 pm

Plenary Session Speaker # 1: Simon Gisby, Managing Director, Global Practice Leader Life Science and Healthcare, Deloitte Corporate Finance LLC; Principal, Deloitte Transaction and Business Analytics LLP

Investment Forecast and COVID-19's Impact on the Pharma and Healthcare Industry

The pharmaceutical and healthcare industry has been witnessing a boom in both scientific breakthroughs and capital investment. While the devastating impact the global pandemic has had on the worldwide economy and the incredible strain on the health care system is well documented, it has also, arguably, fundamentally challenged and changed many orthodoxies. The rapid adoption of virtual health has challenged the idea that healthcare can only be delivered in a physical setting. Pharmaceutical companies are embracing artificial intelligence to accelerate clinical trials. Regulators are approving treatments and testing in record time. The value of sharing personal data has become apparent. Following the new trends, global investment has also been adjusting its focus and strategies.

This presentation will review some key observations from the past year on capital market, explore new changes that emerged, and discuss their impact on the pharmaceutical and healthcare industry as well as future investment themes.

1:20 pm – 1:40 pm

Plenary Session Speaker # 2: George Dai, PhD, MBA, Co-Chief Investment Officer and Senior Managing Director, Weatherbie Capital, LLC

Public Market Perspective – 2020 & Beyond

This presentation will feature an on-going story since the beginning of 2020. We will discuss onset of Covid-19, its impact on the human society and US economy, progresses made in detection methods and personnel protection equipment, efforts in advancing vaccines and treatments. In parallel, we will discuss the steps taken by the US government & global central banks and their impact on the US stock market performance.

1:40 pm – 2:00 pm

Plenary Session Speaker # 3: Ying Huang, PhD, CFO, Legend Biotech

The Journey towards IPO – from Bench to Nasdaq

Legend Biotech was founded as a GenScript subsidiary in 2014 and incorporated in 2015. In October 2015, an investigator-initiated Phase 1 trial (LEGEND-2) of LCAR-B38M was initiated in China, enrolling a total of 74 patients with RRMM. The preliminary results of LEGEND-2 were reported at ASCO 2017 for the first time. In December 2017, Legend entered into a global collaboration agreement with Janssen on development of LCAR-B38M (JNJ-68284528). Currently, Legend and Janssen are conducting registration trials in the US and in China. In March and April 2020, Legend raised \$160.5MM in Series A financing. On June 5, 2020 Legend announced pricing of its initial public offering.

2:00 pm – 2:15 pm

Sponsors' presentations highlights and coffee break

2:15 pm – 2:55 pm

Fireside Chat # 1: How to Attract Angel Investment for Your Start-up

It's a daunting task to build a biotech company. Securing angel investment is the very first step to turn idea into a promising biotech enterprise. The panel is aiming to demystify this step. Our panelists include leaders from all aspects of this ecosystem, including angel investor, early stage entrepreneur, and financial services provider. The discussion will cover, but not limited to the following topics:

- What are the resources available in the ecosystem, and what is the role of each key component?
- How to gain a strategic angel investment?

(Continue to next page)

2:15 pm – 2:55 pm

- What are the advantages and potential risks in leveraging cross-board investment?
- What should be considered to build a sustainable biotech enterprise in the early stage?
- What are the potential impacts of Covid-19 on early stage biotech investment?

Moderator:

Xue Liang, PhD, Senior Scientist, Merck

Panelists:

- Yaniv Sneor, Co-Founder, Mid Atlantic Bio Angels
- Haisheng Zhang, PhD, Co-Founder and CEO, Signet Therapeutics
- Lili Zheng, International Tax Partner, Asia Pacific Cross-Border Services leader & Deputy Managing Partner, US Chinese Services Group, Deloitte

2:55 pm – 3:15 pm

Sponsors' presentations highlights and coffee break

3:10 pm – 3:50 pm

Fireside Chat #2: Healthcare Investment Challenges and Opportunities in a Post-COVID-19 World*Session sponsor:*

The COVID-19 crisis has affected societies and economies around the globe and will permanently reshape our world as it continues to unfold. While the fallout from the crisis is both amplifying familiar risks and creating new ones, change at this scale also creates new opportunities for managing systemic challenges, and ways to build back better. Healthcare has typically been viewed as a safe harbor for investors during a crisis. But what about a public health crisis? How can investors gain a foothold, even as the ground shifts beneath their feet? Our distinguished panelists, with deep knowledge and experiences in biopharma, private equity and cross-border business and trade, will share with us their thoughts on the healthcare investment challenges and opportunities in a post-COVID-19 world. The discussion will cover, but not limited to the following topics:

- What are the trends like for private equity activities in the healthcare sector pre- and during the COVID-19 pandemic?
- What is the healthcare M&A and partnering momentum like in the face of COVID-19?
- How will COVID-19 permanently change some aspects of the healthcare sector and what would be the new opportunities for growth and investment?
- What are the new challenges and opportunities for cross-boarder healthcare investment during and post-COVID-19?
- How will the broadened scope of CFIUS affect the healthcare and private equity industries?

Moderator:

James Early, Managing Partner, Tamarack Advisory

Panelists:

- Jing-Shan "Jennifer" Hu, PhD, Senior Advisor at Qiming Venture Partners USA
- Nevena Simidjijyska, JD, Partner, Fox Rothschild LLP
- Mark Young, MBA, Founding Partner, Bridge Point Capital

3:50 pm – 3:55 pm

1:1 Meeting Introduction

Stephen Xue, MS, President of ASNS NJ Consulting LLC

3:55 pm – 4:00 pm

Closing Remarks

Xiaodong Chen, PhD, 2020 SAPA Healthcare Investment and Roadshow Chair; SAPA Executive Vice President; Drug Product Development Team Lead, BMS

4:00 pm – 5:00 pm

Interactive Network Sessions

We will organize several parallel interactive network sessions at this time. Details to be announced at the Forum.

Project List – Part 1

We have received 50 projects from different fields. Here is a list of projects in alphabetical order. 10 selected projects will attend the first round of roadshow on Jun 20th, 2020. All projects will participate in 1:1 meeting with investors.

	Company Name	Founder(s)/ Management Team	Location	Founded Year
1	Ab Initio Medicine, LLC	Lipeng Sun	Rockville, MD, US	2020
2	able cerebral, LLC	Jon Xia, Wayne Shentu	Ephrata, PA, US	2012
3	Akeagen, Inc.	Libin Cui, Yan Liu, Li Xiao, Xiaolin Sun	Delaware	2017
4	Alycorn Bio	Zhaohui Sunny Zhou, Amissi Sadiki, Athul Sanjeev	-	2020
5	AnHeart Therapeutics (Hangzhou) Co., Ltd.	Junyuan Wang, Bing Yan and Lihua Zheng	Hangzhou, China	2018
6	Atomax Pharma	-	NC, US	2019
7	Avidence Therapeutics	Ang Li	Delaware, US	2018
8	BabelBark	Roy Stein, Bill Rebozo, Rob Christensen, Bruce Truman	DE, US	2015
9	BalinBac Therapeutics, Inc.	John Gregg, Michael Rosenberg, William Zimmermann, etc	Princeton, NJ, US	2014
10	BIOBOHEMIA, INC.	Petr Lokhov, Rafael Avakyan, Aleksey Krylov, Steven Lichtenberg	DE, US	2019
*11	Biosion, Inc.	Mingjiu Chen, Hugh M Davis, Mark Ma	Nanjing, China and Newark, DE, US	2013
12	BIOTECH & BIOMEDICINE (SHENYANG) GROUP LTD.	Xiushan YIN	Shenyang, Liaoning, China	2016
*13	Clerio Vision	Mikael Totterman, Alex Zapesochny, Trevor McCaw, Jay Baker	Rochester, NY, US	2014
14	Cyrcadia Asia, Inc.	Rob Royea, Mark Channells, Chris Bailey etc	Hong Kong, China	2017
15	DotBio Pte. Ltd.	Pär Nordlund, Ignacio Asial, Kelly Hew etc	Singapore, Singapore / Hong Kong SAR, China	2017
16	Dupage Medical Technology, Inc	Xiaoping Du, Minyi Gu, William Wang, Randal A. Skidgel	Chicago, IL, US	2012
17	Equilibre Neuroscience	Sam Waksal, Rui Wu, Gregory Petsko, Scott Small	New York, NY, US	2019
18	Excyte LLC	Andy Yuan, Qingwu Meng	Rockville	2016
19	ExonanoRNA	Peixuan Guo, Fengmei Pi, Mario Vieweger	Columbus	2018
20	Forkhead BioTherapeutics	Domenico Accili, Charles Queenan, Hua Lin	New York, NY, US	2017
21	FrontAim Biomedicines, Inc.	Bill (Donglin) Liu, Steven (Huaiyu) Chi, Wenge Cui	Princeton, NJ, US	2018
22	FZata, Inc.	Zhiyong Yang, Hanping Feng, Jibin Zhao, Elizabeth Smith	DE, US	2015
23	Genolmmune	Bo Li, Naibo Yang, Jinyu Li, Jun Li	Wuhan, Hubei, China	2017
24	GI Biopharma Inc	Xiaofa Qin, Ning Yan, Shuqin Zheng	Westfield, NJ, US	2014
25	GV20 Oncotherapy	X Shirley Liu, Ted Xiao, Sherlock Hu, Stephen Landau	Cayman	2016

*Project selected for oral presentation in the first round of Roadshow Session on June 20.

Project List – Part 2

We have received 50 projects from different fields. Here is a list of projects in alphabetical order. 10 selected projects will attend the first round of roadshow on Jun 20th, 2020. All projects will participate in 1:1 meeting with investors.

	Company Name	Founder(s)/ Management Team	Location	Founded Year
*26	HbO2 Therapeutics LLC	Zaf Zafirelis, Igor Serov, Gregory Dube etc.	Souderton, PA, US	2014
*27	Innovative Cellular Therapeutics, Inc.	Lei (Larry) Xiao, Zhao (Zoe) Wu etc.	Delaware, US	2018
*28	KLUS Pharma	Tongtong Xue, Jingyi Wang	Cranbury, NJ, US	2014
29	Levadura Biotechnology Inc.	Matt Engler, Alex Hutagalung, Jose Laplaza, Brian Conn	San Diego, CA, US	2018
*30	LinkedUp Bioscience	Greg Li, Stephen Gillies, Tao Wang, Jason Lavinder	Delaware/Massachusetts	2018
31	Lotus Biopharma Inc	King-Teh	Monmouth Junction, NJ, US	2019
32	LUNAGEN AG	Peter Truog, Cheung Shek Lun, Ru Hoang-Li, Gao Tai Ping	Chur, Grisons, Switzerland	1979
33	Manzara Therapeutics Inc.	Raghav Chari, Herschel Rabitz	Wilmington, DE, US	2017
*34	Misum Biotech	Don Liu, David Rowe, James Dermody, Jiegen Jiang	Dalaware, US	2017
35	Molecular Theranostics, LLC	Zheng-Rong Lu, Yajuan Li, Michael Tweedle	Cleveland, Oh, US	2014
36	Mononuclear Therapeutics Limited	Wise Young, Ken Giacini, Wendy Cheng, Chi Kong Li	Hong Kong, China	2015
37	Nanjing Gemini Biotechnology Co., Ltd	Shidong Song, Jingwei Jiang, Yuanyuan Sun	Nanjing, Jiangsu, China	2015
38	Neomics Pharmaceuticals	Wenshan Hao, Jianming Lu, Wei Zhu	Gaithersburg, MD, US/Cayman Islands	2019
*39	Phase Scientific International Limited	Ricky CHIU, Dan MARSHAK, Leslie CHOW, Bing LIU	Hong Kong, China	2017
*40	Quantapore	Martin Huber, Brian Conn, Martin Doyle	South San Francisco, CA, US	2011
41	Shanghai Jiangxia Blood Technology Co. , Ltd.	Shaojun Chen, Ye Sheng, Xingyan Chen, Heping Huang	Shanghai, China	2001
42	SinoBioPrint (Shanghai) Biotech Ltd.	Harry Chen, Guangde Lai, Sophie Cheng, Edison Huang, etc	Shanghai, China	2018
43	Sterling Pathology Natl Labs	Changgao Yang	Seal Beach, CA, US	2003
44	Sungen Pharma	-	Wilmington, DE, US	2016
45	Teclison Limited	Ray Lee, Haikun Shi	Cayman Islands	2013
*46	Teon Therapeutics, Inc.	Lina Yao, Ken Horne, Peidong Fan, Jim Liu, Al Elzein, Bob Sikorski	Delaware, US	2018
47	V and M International LLC	Shelby Zhu and others	US	2004
48	Vivacitas Oncology	Jeffrey Stephens, Mamta Swaroop, etc	Walnut Creek, CA, US	2016
49	X-Therma	Xiaoxi Wei, Mark Kline, Eli Mohamad	Berkeley, CA, US	2015
50	Zenena Technologies Inc.	Rachel Chase, Oliver Luo etc.	Vancouver, BC, Canada	2017

Biographies of the Presenters, Panelists, Investors and Roadshow Judges

Arranged alphabetically by the last names



Daqing (Darren) Cai, PhD

Founder and Managing Partner, Sherpa Healthcare Partners

Dr. Daqing (Darren) Cai is a founder/Managing Partner of Sherpa Healthcare Partners. Before establishing Sherpa Healthcare Partners, he was a Managing Director at Legend Capital and a leader of the Healthcare investment team.

Dr. Cai focuses on investment opportunities in the healthcare sector and he led LC's investments in companies including Berry Genomics (SZSE: 000710), Innovent (HKE: 1801B), New Horizon, Shenogen, BioHermes, Ribo, Axonics (NASDAQ: AXNX), BioNano (NASDAQ: BNGO), Hemay, PegBio, Singular, T-Cure, Indi Molecular, NanoVision, Leto Labs, Memoray, Belief Bio, and many others.

Dr. Cai received multiple awards for Top 10 Healthcare Investors in China. He was one of Forbes Best VC Investors in China in 2017. In 2018, he was elected Co-Chairman of Healthcare Investors 50 (H50, a top Chinese Healthcare investor organization) for 2018-19.

Prior to joining Legend Capital, Dr. Cai worked at SBI-SDJB, a joint venture fund of SBI Group and Beida Jadebird Group as a Managing Director. He also worked for SinoChem (Hong Kong) and Booz & Co. in senior management positions. He was a Board Director and CFO of Beijing Genomics Institute (300676.SZ) as well.

Dr. Cai holds a Ph.D. degree from University of California, Berkeley; an MBA from Yale University; and a B.S. degree from University of Science and Technology of China.



Kan Chen, PhD

Principal, Qiming Venture Partners

Dr. Kan Chen is a Principal of Qiming Venture Partners, focusing on healthcare investment. Before joining Qiming Venture Partners, Kan was a senior scientist at Johnson&Johnson discovering innovative cancer medicine. Prior to that, Kan was a group leader at Jiangsu Hengrui Medicine, developing new cancer immunotherapies



George Dai, PhD

Senior Managing Director
Co-Chief Investment Officer, Weatherbie Capital, LLC

George Dai is Senior Managing Director and Co-Chief Investment Officer of Weatherbie Capital, LLC. George is a Portfolio Manager on the Alger SMidCap Focus Fund, the Alger Dynamic Opportunities Fund, the Weatherbie Specialized Growth Strategy and the Weatherbie Long/Short Strategy. Under his leadership, The Alger SmidCap Focus Fund has achieved top performances in recent years, including being ranked as #1 in the Mid-Cap Growth Category during the first quarter of 2019, which has been featured by a New York Times article and a Reuters Television interview. George received his MBA from the Wharton School, University of Pennsylvania, (Director's List), and his Ph.D. in chemistry from Johns Hopkins University. Previously, he earned a B.S. from the University of Science and Technology of China and was a pharmaceutical research scientist at Procter & Gamble. George is a prized Bridge player, and he holds four U.S. patents.



Simon Gisby

Managing Director, Global Practice Leader Life Science and Healthcare, Deloitte Corporate Finance LLC
Principal, Deloitte Transaction and Business Analytics LLP

Mr. Gisby is a senior Corporate Strategy and M&A professional with over twenty years of experience serving the Life Science and Healthcare industries. As well as founding and leading the Life Science and Healthcare Corporate Finance practice, he is a co-leader in Deloitte's Virtual Health and Value Based Care practices and leads The Future of Health for Deloitte Advisory.

Mr. Gisby has advised on numerous strategy, affiliations, partnerships, and M&A engagements. He is currently focusing on facilitating ecosystem partnerships across the entire life science and healthcare ecosystem. His clients include global pharmaceutical and medical device companies, health insurance companies, health systems, healthcare information technology companies and other healthcare providers.



Jing-Shan "Jennifer" Hu, PhD

Senior Advisor, Qiming Venture Partners USA

Dr. Jing-Shan "Jennifer" Hu is Senior Advisor at Qiming Venture Partners USA. She has worked in VC investment on innovative therapeutics in the U.S. since early 2016 for various firms with roles including Senior Advisor, Venture Partner, Founding Partner (Qiming Venture Partner U.S. Healthcare Fund I). Her success in investment includes leading a \$67M series C1 financing of AMRO, followed by its successful IPO on NASDAQ and acquisition by Eli Lilly with \$1.6Bn cash.

Before joining the VC world, she has worked for over 20 years in partnering/licensing, business development, R&D at three multinational pharmaceutical companies and two biotech companies in the U.S. with various roles, including VP and Head of (External) Innovation Center China at Bayer Healthcare Pharmaceutical, Director of Licensing & External Research at Merck&Co (MSD); Head of Functional Biology at Roche Palo Alto, Program Manager of Pharmacogenomics at Affymetrix, and Scientist of Protein Therapeutics at Human Genome Sciences.

Dr. Hu obtained her post-doctoral training at Harvard Medical School, a PhD from University of Texas Graduate School of Biomedical Sciences at MD Anderson Cancer Center, and a BS from Peking University.



Ying Huang, PhD
CFO, Legend Biotech

Ying Huang, PhD, has served as CFO of Legend Biotech since July 2019. Prior to joining Legend, Dr. Huang was a Managing Director and Head of Biotech Equity Research at Bank of America Merrill Lynch from August 2014 to July 2019, where he led a team of analysts covering more than 30 biotechnology companies including Amgen, Gilead, Celgene, Biogen and others that encompass a wide range of therapeutic areas. Dr. Huang has been a biotechnology analyst since 2007 and previously worked at Wells Fargo (formerly Wachovia), Credit Suisse, Gleacher and Barclays before joining Bank of America Merrill Lynch. Prior to his Wall Street career, Dr. Huang was a Principal Scientist at Schering-Plough (now Merck & Co.) in the Department of Chemical Research focusing on small molecule drug discovery in the therapeutic areas of cardiovascular and central nervous system. He is also the co-author of multiple patents and peer-reviewed publications. Dr. Huang holds a Ph.D. in Bio-organic Chemistry from Columbia University. Dr. Huang also studied at Columbia Business School and in the Special Class for the Gifted Young at the University of Science and Technology of China.



Praveen Kudithipudi, MD, MBA
Director of Business Development, Fannin Innovation

Dr. Praveen Kudithipudi is a medical doctor trained in Neuroscience in the United Kingdom and has over 15 years of expertise in Healthcare Investment Banking, Venture Capital, Investment Management, Business Development, Strategy and Entrepreneurial Initiatives.

Dr. Kudithipudi serves as Director of Business Development at Fannin Innovation Studio, Houston, Texas supporting licensing of pharmaceutical drugs and establishing collaborations with Pharmaceutical companies and Academia. Fannin is an Incubator/Venture Capital firm and currently has 12+ technologies in the portfolio with investments exceeding \$140+ Million. Dr. Kudithipudi also serves as a Senior Vice President in Healthcare Investment Banking at WestPark Capital, New York.

Dr. Kudithipudi received a MBBS (MD) in Medicine from Manipal University, India and MBA in Finance from New York University, USA. He is the exclusive author of a medical book sold on Amazon.



Nevena Simidjyska

Partner; Co-Chair of the International Trade Group; Chair of the Philadelphia Corporate Department, Fox Rothschild LLP

Nevena advises public and private companies in a variety of transactional and corporate finance matters, including mergers and acquisitions and lending and secured transactions.

Co-Chair of the firm's International Trade Group, Nevena advises clients on export licensing, economic sanctions, and related internal controls, including compliance under the Export Administration Act, the International Traffic in Arms Regulations (ITAR), and the Office of Foreign Assets Control (OFAC). Nevena also advises clients on the restrictions on foreign investment and acquisition of US companies and counsels them through the review process conducted by the Committee on Foreign Investment in the United States (CFIUS).



Yaniv Sneor

Co-Founder, Mid Atlantic Bio Angels

Yaniv Sneor is one of the founders of MABA – Mid Atlantic Bio Angels, a life science angel investor group, where he also administers MABA's internal investment pools, and MABA's co-investment Sidecar Fund for non MABA member investors. Mr. Sneor is also Chief Executive Officer of Native State Therapeutics, an early state biotechnology company in the neurodegeneration field, and President of Blue Cactus Consulting, a business strategy consulting group.

Yaniv Sneor is originally a physicist, who made the transition into the business world about 30 years ago. Mr. Sneor has senior merger, acquisition, capitalization, turnaround leadership experience with companies ranging from start-up to growth. He has held positions of CEO, COO, President, and General Manager at a number of companies, including a bio-informatics company, a surgical laser company, a manufacturing and distribution company, a software and network integration company, and several others.

Mr. Sneor has mentored numerous life science and technology start-ups through BiomedX, the Bench-to-Bedside Initiative jointly sponsored by Weill-Cornell Medical Center, and the E-Lab for Life Science Entrepreneurs sponsored in part by the New York City Economic Development Corporation.

Until recently, Mr. Sneor was a member of the Board of Trustees of the Institute for Life Science Entrepreneurship, is currently a member of the NJ EDA's Technology Advisory Board, and a past Chairman of the NJ chapter of the Licensing Executives Society (LES).



Jin Wang, PhD

Managing Partner, Manhattan Capital Group

Dr Wang is the Founding Partner of MCG Group, and former Asia/China Head of Paramount Capital VC Group. With over 20 years experience of biotech VC investment in US and China, he actively invested 30+ startups in biotech/ healthcare field since the

late 1990s. Prior to his VC career, Dr Wang worked for Roche and academia research, after obtained his bachelor degree from Zhejiang University and graduated from WPI for his PhD. He is co-founder of the SAPA organization, co-founder and early investor of many companies including DXY company.



Mingde Xia, PhD

Senior Director, Johnson & Johnson Global External Innovation

Dr. Mingde Xia is currently a Senior Director of WWDA, Johnson & Johnson Global External Innovation. He focuses on business partnership through investment, incubation, co-development, license and other collaboration vehicles. He has been working with Johnson & Johnson since 1999 after career track at China Pharmaceutical University and Yale University, and has successfully led / executed over 50 projects external collaboration for Johnson & Johnson three sectors (Pharm / Medical Device / Consumer). He is a guest / adjunct professor at the Chinese Academy of Sciences, a major inventor / author of over 60 patents / publications, a reviewer for a number of top quality international scientific journals, and an invited speaker for many international pharmaceutical conferences / forums. He received awards from American Chemical Society, Johnson & Johnson and different universities. He has actively involved in Sino-American Pharmaceutical Professionals Association (SAPA President 2008, Board of Directors 2008-present) and organized many international conferences in USA and Asia.



Chong Xu, PhD

Principal, F-Prime Capital

Chong is a Principal at F-Prime Capital. He focuses primarily on biopharmaceutical and medical technology sectors and works closely with the Eight Roads Ventures Asia team to manage portfolio companies and new investment opportunities in China. Prior to joining F-Prime in 2015, Chong was an associate in McKinsey and Company's Boston office, a hedge fund healthcare equity analyst with Massif Partners and Affirmed Healthcare, and a researcher focusing on developmental neurobiology at Temasek Life Sciences Laboratory in Singapore.

Chong holds a Ph.D. in Cell Biology from University of Virginia and a MBA from Darden School of Business, University of Virginia. He received his B.S. in biology from Zhejiang University, China.



Mark Young, MBA, CPA and CFA

Co-Founder/Partner, Bridge Point Capital (Bridge Health Capital Management LLC)

- Co-Founder of Bridge Point Clean (www.bridgepoint-clean.com), Company that provides product and services that help contain the spread of the COVID-19 Virus.

- Co-founder of L Catterton's US\$500 million Latin America Fund, where he also served as Partner and Investment committee member
- Led the Investment Advisory division within McKinsey & Co's Investment office, overseeing ~US\$10 billion in Partner Funds. He successfully implemented the "Endowment Model" for the 3000 McKinsey partners, achieving equity-like returns with bond-like volatility during his tenure
- Co-founded a biotechnology company, Cambridge NeuroScience, raising US\$75 million of private capital from investors including Warburg Pincus and the Harvard Endowment before taking the company public, earning initial investors 1000x MoC
- Graduated from Harvard Business School with an MBA degree in 1993 and has obtained both the CPA and CFA qualifications.



Aaron (Guoxi) ZHANG, DrPH Candidate/MBA
Director, Huagai Healthcare Fund

Mr. Aaron ZHANG is the director of Huagai Healthcare Fund based in Beijing. He focuses on healthcare investment in China, and has over 10 years of enterprise management and investment experience in the healthcare industry.

Prior to joining Huagai Healthcare Fund, Aaron was a senior associate of WI Harper and a co-founder of a medical group in China. He has amassed a wealth of experience in sales, marketing, and medical project management during his time at Pfizer, Novartis and Roche.

Mr. Aaron ZHANG is a DrPH candidate at the Johns Hopkins Bloomberg School of Public Health, he holds an M.B.A. from Guanghua School of Management in Peking University and a B.S. in Pharmaceuticals.



Lili Zheng
Partner, Deloitte Tax LLP

Ms. Lili Zheng is a senior US international tax partner at Deloitte with more than 30 years of experience. She is Deloitte's Asia Pacific Cross-Border Services Leader and Deputy Managing Partner of Deloitte US Chinese Services Group. She is responsible for Deloitte's overall cross-functional services to MNCs investing Asia as well as Chinese & Asian clients investing in the US. Ms. Zheng provides practical and implementable solutions to clients on their cross-border investment structuring, IP planning, JV planning, M&A, entry and exit strategies. She is a trusted advisor with substantial experience in advising PE/VC funds and their portfolio companies in IPO positioning & restructuring to access different capital markets in the US, Mainland China, Hong Kong and Taiwan. She also has extensive experience in servicing clients at different growing stages and from different industries, including life science & healthcare, financial services, manufacturing, and technology. Fluent in Mandarin and Cantonese, Ms. Zheng has a deep understanding of the unique considerations of companies from Asia Pacific. She received her B.S. in Accounting and Finance from UC Berkeley and M.S. in Taxation from Golden Gate University.



Haisheng Zhang
Co-founder and CEO, Signet Therapeutics

Haisheng Zhang is the co-founder and CEO of Signet Therapeutics. Signet therapeutics is developing novel kinase inhibitor to target stomach cancer and breast cancer.

Haisheng Zhang has been trained as a Postdoctoral Research Fellow at Dana-Farber Cancer Institute, Harvard Medical School. He has been awarded two postdoctoral fellowships: one is Horizon Award from "Department of Defense" and another is Debbie's Dream Foundation from AACR. His postdoctoral work was published in Cancer Discovery. He was the co-President of MIT-CHIEF.



Hongjian Zhang, PhD
Managing Director, Morningside Ventures

Dr. Hongjian Zhang is a managing director of Morningside Ventures with 20+ years of academic research, pharmaceutical R&D, management and investment experiences. Previously, Dr. Zhang was a board member of Sirius Investment Co, Ltd and served as CEO for its portfolio companies engaged in trans-pacific R&D and business operation. Prior to that, He was a co-founder and COO of PharmaResources (Shanghai) Co, Ltd., and a senior project leader at Bristol-Myers Squibb Pharmaceutical R&D. Over the years, Dr. Zhang directed and advanced more than 16 drug candidates to various stages of clinical trials spanning several therapeutic areas. Aside from his industrial commitment, Dr. Zhang enjoys translational research and is currently an adjunct professor at College of Pharmaceutical Sciences, Suzhou University, with 80+ publications in peer-reviewed journals. Hongjian obtained his PhD degree from University of California-Davis and completed his postdoctoral training at National Institutes of Health (NIH).

Investors Participating the Forum (1)

F/PRIME



MORNINGSIDE
VENTURES



KnighT



Lilly 礼来亚洲基金
Asia Ventures



MAGNET



Johnson & Johnson INNOVATION



Investors Participating the Forum (2)



美国中经合集团

WI HARPER GROUP

SAN FRANCISCO | TAIPEI | BEIJING



澜亭资本




阳和投资
Yanghe Investment



Kingdon Capital



LEGENDARY VENTURES



Pharma and Others

AstraZeneca 

Baxter

 **Boehringer
Ingelheim**

 **CASI**
Pharmaceuticals

FOSUN PHARMA
复星医药

 **恒瑞医药**
HENGRUI MEDICINE

 **华海药业**
HUAHAI PHARMACEUTICAL



人福医药
HUMANWELL HEALTHCARE



科伦集团 INDUSTRY GROUP

 **康龙化成**
PHARMARON

 **Takeda**

Event Sponsors

Title Sponsor

Deloitte.

Session Sponsor

 **Fox Rothschild** LLP
ATTORNEYS AT LAW

General Sponsors


杭州湾生命科技园


BRIDGE
POINT CAPITAL


恒瑞
Hengrui Medicine


科伦药业
KELUN PHARMACEUTICAL


Medicilon


mgo
TYPE ATYPICAL

CPAs &
Advisors



WWC Professional
Corporation Limited, CPA

2019-2020 SAPA Corporate Sponsors

Diamond Sponsors:



Platinum and Gold Sponsors:



BRIDGE POINT CAPITAL

HEALTHCARE PRIVATE EQUITY & FINANCIAL ADVISORY SERVICES

152 W57th Street, Carnegie Hall Tower, 49th Floor.
New York, NY 10019
info@bridgepoint.capital


ABOUT US

Bridge Point Capital is a growth-focused **U.S & China cross-border private equity** and a **financial advisory services firm** with unique expertise in monetizing and marketing disruptive healthcare technologies including solutions for the **COVID-19 outbreak**. We have launched a separate initiative, **Bridge Point Clean***, to tackle the COVID-19 outbreak. Our team has exceptional hands-on experience in the financial and healthcare industries, leveraging a proprietary network with both investors and operators to create long-term value for our clients.

MARKET OPPORTUNITY

- According to Fidelity Investment, the **U.S. Healthcare** sector has consistently **outperformed in late stages**, as healthcare-related revenues are more insulated from economic underperformance.
- The rapidly aging Chinese population generates huge demand for healthcare products and services. The United Nations estimates that by 2050, **~27%** of China's population will be **aged 60** or over.
- China's healthcare reformation will support robust growth in domestic healthcare expenditure and foreign investment. China's State Council Healthcare Market is expected to reach **¥ 16,000 billion RMB** by 2030.

China's Proportional Mortality Caused by Non-Communicable Diseases (NCDs)



PRIVATE EQUITY PLEDGE FUND

Well-positioned to achieve venture returns with reduced risk and higher liquidity by investing in late-stage venture-backed healthcare companies while also capitalizing on China's robust healthcare demand to strategically create value. Our Pledge Fund structure gives our investors the option to participate at their sole discretion, providing unmatched flexibility and transparency.

CO-INVESTMENT PLATFORM

The demand for fresh capital to meet the funding gap of small VC's largest deals is increasing. We partner with small VCs to provide a funding solution and an additional revenue source to early-stage VCs who are having difficulties funding follow-on rounds. We help VCs to utilize their pro-rata participation rights to capitalize on the previously unfunded investments while also maintaining governance rights.

FINANCIAL ADVISORY

Utilizes our deep China expertise, proprietary network of U.S healthcare and financial institutions to help western companies access the China market as well as help Chinese firms develop business opportunities in the U.S. We aim to create long-term value for our clients from assisting with partner sourcing all the way to deal structuring and deal closing.



*At **Bridge Point Clean**, we have invested extensively in the latest cleaning technology to ensure a safer environment in response to the **COVID Outbreak**. We hope to provide and educate our clients with cleaning and decontamination services while maintain maximum quality and efficiency in timing.

MANAGEMENT TEAM



MARK YOUNG | FOUNDING PARTNER

- Co-founder of L Catterton's **US\$500 million** Latin America Fund, served as Partner and Investment committee member.
- Led the Investment Advisory division within McKinsey & Co's Investment office, overseeing **~US\$10 billion** in Partner Funds. He successfully implemented the "Endowment Model" for the **3000 McKinsey partners**, achieving equity-like returns with bond-like volatility during his tenure.
- Co-founded a biotechnology company, Cambridge NeuroScience, raising **US\$75 million** of private capital from investors including Warburg Pincus and the Harvard Endowment before taking the company public, earning initial investors **1000x MoC**.



NADIA TIAN | FOUNDING PARTNER

- Worked with local Chinese government and technology parks to source deals. The overall funding capabilities of these technology parks exceeded **~¥200 million RMB**.
- Business Unit Manager at Goldman Sachs Asset Management's Investment Management Division, where she was responsible for developing sales strategy for RIA, Banks and ICG channels in the mutual fund division. She also managed the launch of two Closed-End Funds from 2013-2015, each with over **US\$500 million AUM**.
- Advised both non-profit and for-profit businesses in Ghana, Tanzania, Haiti, Mexico and Swaziland to help improve operations, secure funding, and expand into new markets.

We are proud to support

SAPA

and wish great success with the
2020 SAPA Healthcare Investment Forum & Roadshow

**ENTREPRENEURIAL. NIMBLE.
RESPONSIVE.**

**QUALITIES YOU LOOK
FOR IN A LAW FIRM.**

WE HEAR YOU.

How has Fox Rothschild grown to 950 lawyers?

By attracting bright, creative attorneys who focus on client service, solve problems and deliver results.

We equip our lawyers with the resources to nurture innovation and drive client success.

Better lawyers. Happy clients.

We like the sound of that.




Fox Rothschild LLP
ATTORNEYS AT LAW

950 attorneys nationwide


Wansheng Jerry Liu, Ph.D., J.D.
Partner & Chair of China Practice

SAPA President 2019-2020

609.844.3037 | wliu@foxrothschild.com



Hengrui Medicine: The Largest Publicly Traded and a Leading Biopharma based in China, Devoted to Empowering Healthier Lives through Research






KLUS PHARMA

Antibody-Drug Conjugates (ADC)

Bispecific Antibodies



Biologics Discovery and Development

ABOUT US

Founded in 2014 as a subsidiary of Kelun-Biotech, KLUS Pharma is committed to the discovery and development of innovative biotherapeutics. Our top priority is to address the unmet needs of patients suffering from cancer, cardiovascular disease, autoimmune disease, and other severe disorders due to lack of effective treatment options. Utilizing our innovative technology platforms for monoclonal antibodies, bi-specific antibodies, and Antibody-Drug Conjugates (ADCs), we have advanced multiple biologic programs into the clinical stage. Supported by our team of industry experts in oncology, immunology, and cardiology, we have identified and assessed dozens of therapeutic targets including TROP2, TIM-3, LAG-3, and Claudin 18.2.

KLUS Pharma has a proprietary discovery and development platform for therapeutic antibodies, which provides full coverage on all key development steps into clinical stages. Our third-generation ADC platform resulted in high affinity and internalization activity for multiple drug candidates in addition to demonstrated safety benefits. Since no bispecific design has been singled out as the best, our development platform for bispecific antibodies supports a variety of bispecific formats in order to maximize the efficacy for each target and MOA

OUR MISSION

KLUS Pharma focuses on the needs of patients lacking effective treatment options and aims to combat life-threatening diseases with the discovery and development of novel and safer antibody-based therapeutics.

– INNOVATION –
– INTEGRITY –
– COLLABORATION –



Business Development

KLUS Pharma believes the best practice to accelerate drug development is through value creation for all parties in a “win-win-win” alliance.

We welcome any opportunity to collaborate with innovators, potential partners, and investors. If you have a business proposal or inquiry, please contact us at bd@kluspharma.com

Address: 8 Clarke Drive, Suite 4,
Cranbury, NJ 08512
Phone: 609-662-1913

Fax: 609-662-1918

Pharmaceutical and Life Sciences

Empowering the Next Breakthrough

Focused Guidance for the Pharmaceutical and Life Sciences Sectors

Financial pressures, disruptive technologies, and regulatory red tape are among the obstacles Pharmaceutical and Life Sciences executives must overcome in pursuit of innovation. Guidance powered by technical accuracy and deep industry insight can give your organization a competitive edge when launching new products, raising capital, and conducting complex transactions.

MGO serves leading Pharmaceutical and Life Sciences companies at every stage of growth – from dynamic start-ups to global powerhouses. Our accounting, advisory, and financial services help companies streamline finances, maintain regulatory compliance, and mitigate risk on the path to achieving strategic growth.

Proven Expertise and Scalable Solutions

MGO's suite of services optimized for Pharmaceutical and Life Sciences industries include:

- Audit (Private and Public)
- Forensic Accounting
- Tax Compliance & Advisory
- Tax Credits & Incentives
- International Tax Planning & Transfer Pricing
- CFO Outsourcing and Technical Accounting Services
- Business Valuation
- Mergers & Acquisitions
- Governance & Risk Compliance
- Grant Audit & Accounting Services

What Our Clients Say:

"MGO is a trusted and reliable audit professional to Amyris, Inc. While under an extremely tight deadline with intense time pressure, MGO's recent audit of Amyris' financial statements was thorough, focused, and insightful. MGO clearly has the technical expertise and resources to respond to a firm as large and complex as Amyris, Inc., and also provides the personal touch and attention that is unusual. It is a pleasure working with a firm in whom we have complete confidence." *-Jonathan Wolter, Interim CFO*

Select Clients:

Beroni Group	FibroGen	Sophiris Bio
Align Technology	Forty Seven	Thermo Fisher
Amgen	Genomatica	
Amyris	Gilead	



Experienced Leadership



Steven Kreit, CPA
SEC Practice Leader &
Assurance Partner
skreit@mgocpa.com
+1 (212) 441-3171



Joanne Chiu, CPA
Managing Director of Asia
Practice
jchiu@mgocpa.com
+1 (212) 441-3168
WeChat: joannchiu (or
scan the QR code below)



BIOVILLAGE

杭州湾生命科技园



BIOVILLAGE

杭州湾生命科技园

公司简介 COMPANY PROFILE

杭州湾生命科技园BIOVILLAGE先期启动区已于2018年7月正式投用，设施完备、装修时尚，已有美国哈佛大学教授创业项目等在内的数家新药研发企业入驻园区，其中2家创业企业获得了宁波市创新创业“3315计划”的资助。

简介：已全面启动建设的生命科技园新园区占地100亩，将建设生物医药创业孵化楼、企业联排、公共服务平台等组成的共计6万多平米国际化、花园式科技园区，园区一期将于2020年投入使用。

优势：BIOVILLAGE通过与康龙化成公司的紧密合作，入园创业者将享有零距离、专业化、国际一流的外包服务，以更低的创业成本、更短的创业周期达成创业成功。



杭州湾生命科技园 BioVillage
中国·宁波·杭州湾新区滨海四路 800 号

联系人
冯莎 (Sarah) sarahfeng@biovillage-nb.com
沈燕 (Ella) ella@biovillage-nb.com





Stock (Shanghai)
688202

Innovation Driven Quality Focused

Integrated Preclinical Drug R&D Service
Medicilon Accelerates Your New Drug Research Process

About Medicilon

- 16 Years R&D Experience Since 2004
- 800 Worldwide Active Clients
- 1500 Employees Globally
- 700,000 SQ.FT of Lab and Research Facilities

Services



Drug Discovery

Chemistry
Biology



CMC

API
Formulation
Analytical Chemistry



Preclinical Studies

Pharmacodynamics
Pharmacokinetics
Drug Safety Evaluation



Please Follow Our WeChat

Medicilon Headquarter (Shanghai) Address: 585 Chuanda Road, Shanghai 201299, China

Tel: +86 (21) 5859-1500 Fax: +86 (21) 5859-6369 Email: marketing@medicilon.com Website: www.medicilon.com

Customer Service: 400-780-8018 (Mainland China) | +86 (21) 5028-2001 (Global)



WWC Professional Corporation Limited Certified Public Accountants

WWC Professional Corporation Limited (the “Firm”) is a boutique professional services firm, established in 1981, with headquarter in Silicon Valley, with offices in Hong Kong, Beijing, and New York. The Firm’s partners are seasoned veterans with experienced accumulated from various disciplines, both in the corporate and professional practice side. The Firm provides a full suite of financial and corporate services to clients, including, assurance and attestation, tax advisory and compliance, capital market transactions support, management consulting, and corporate services.

Through the years, the Firm has established itself as a trusted advisor to its clients around the world. The Firm prides itself not only on its agility, creativity, and technical prowess, but even more so to its commitment to quality, integrity, and ethics.

Globally, the Firm serves more than 500 clients across diverse sectors, industries, and geographies, which includes companies listed on national stock exchanges and over-the-counter markets.

<p style="text-align: center;">ASSURANCE</p> <ul style="list-style-type: none"> • Financial statement audit • Financial statement review • Annual/interim report and announcement review • Internal control review and attestation • Regulatory compliance • Agreed Upon Procedures 	<p style="text-align: center;">TAX ADVISORY & COMPLIANCE</p> <ul style="list-style-type: none"> • Holistic tax planning, especially for companies with operations in Hong Kong, China and the US • Transfer pricing studies • Tax filing and compliance: <ul style="list-style-type: none"> • Profits and income tax • Salaries and payroll tax • Property tax 	<p style="text-align: center;">MANAGEMENT CONSULTING</p> <ul style="list-style-type: none"> • Operational process improvement • Back-office optimization, including, Finance, HR, IT, & Procurement functions • Large scale finance transformation, including shared services and ERP implementation • Working capital management
<p style="text-align: center;">CORPORATE SERVICES</p> <ul style="list-style-type: none"> • Accounting advisory • Bookkeeping • Company secretarial for listed and private companies • Incorporation of Hong Kong, US and offshore companies • Company Registry compliance matters • Registered Office 	<p style="text-align: center;">DEALS ADVISORY</p> <ul style="list-style-type: none"> • Deals identification • Buy-side / sell-side identification and coordination • Financial due diligence for capital market transactions • Commercial diligence • Financial advisory • Post deal integration 	<p style="text-align: center;">CAPITAL MARKET</p> <ul style="list-style-type: none"> • IPO readiness assessment and preparation • Advise on stock exchange requirements • In-depth industry and market analysis • Financial Advisory • Act as Reporting Accountant

Career Development Workshop



Sino-American
Pharmaceutical
Professionals
Association

Blaze the Trail

*Work smarter
Not just harder*

Saturday
July 18, 2020



**Save
the
Date**



Saturday, August 15, 2020

2020 SAPA Scientific Symposium

**Save
the
Date**



Sino-American
Pharmaceutical
Professionals
Association



Sino-American
Pharmaceutical
Professionals
Association



2020

SAPA

Annual Conference

Science ♦ Education ♦ Collaboration ♦ Career

October 2 – 3, 2020

DoubleTree by Hilton

Somerset Hotel and Conference Center

200 Atrium Drive

Somerset, NJ 08873, USA





Sino-American Pharmaceutical Professionals Association

PO Box 282
Nanuet, NY 10954
USA

SAPA Mission:

- To promote the advancement of pharmaceutical science and biotechnology
- To make contributions benefiting public health education
- To promote scientific exchange and business cooperation between US and China
- To foster the career growth of pharmaceutical professionals

Follow SAPA on:

Website: <https://sapaweb.org>
Weibo: <http://weibo.com/sapaweb>
LinkedIn: SAPA-HQ
Twitter: @SAPA_001
WeChat: SAPA

